{
    "body": "List features of the DEND syndrome.", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23382304", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22145471", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22326206", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20368737", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23783767", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17652641", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24150202", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16670688", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16019717", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23462667", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22768671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16609879", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16123337", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22694282", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19169493", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19686306"
    ], 
    "ideal_answer": [
        "Clinical features of the DEND syndrome include developmental delay, epilepsy and neonatal diabetes."
    ], 
    "exact_answer": [
        [
            "developmental delay"
        ], 
        [
            "epilepsy"
        ], 
        [
            "neonatal diabetes"
        ]
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577", 
        "http://www.disease-ontology.org/api/metadata/DOID:225"
    ], 
    "type": "list", 
    "id": "56c1f030ef6e39474100004d", 
    "snippets": [
        {
            "offsetInBeginSection": 116, 
            "offsetInEndSection": 252, 
            "text": "Some mutations in this gene, including p.Q52R, are associated with the developmental delay, epilepsy, neonatal diabetes (DEND) syndrome.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24150202", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 657, 
            "offsetInEndSection": 759, 
            "text": "Developmental delay was noted on follow-up which raised the possibility of intermediate DEND syndrome.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23783767", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 223, 
            "offsetInEndSection": 436, 
            "text": "We have verified a lack of clinical response for both glycemic control and neurological features in an infant with permanent neonatal diabetes mellitus and DEND syndrome due to a V59A mutation in the KCNJ11 gene. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382304", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 149, 
            "offsetInEndSection": 282, 
            "text": "They also may cause neurologic symptoms such as mental retardation and motor problems (iDEND syndrome) and epilepsy (DEND syndrome). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23462667", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 294, 
            "offsetInEndSection": 501, 
            "text": " Wide phenotype variability is associated with single ABCC8 mutations, ranging from transient or permanent neonatal diabetes (ND) with or without developmental delay (DEND syndrome) to very mild phenotypes. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22326206", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 124, 
            "offsetInEndSection": 353, 
            "text": "Specific uncommon mutations KCNJ11give rise to a syndrome defined as developmental delay, epilepsy, and neonatal diabetes (DEND), or - more frequently - to a milder sub-type lacking epilepsy, denoted as intermediate-DEND (iDEND).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22694282", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 429, 
            "offsetInEndSection": 756, 
            "text": "Approximately 20% have associated neurologic features: the most severe form, which includes epilepsy and developmental delay, is called developmental delay, epilepsy, and neonatal diabetes (DEND) syndrome and the milder form, with less severe developmental delay and without epilepsy, is designated intermediate DEND syndrome. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768671", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 426, 
            "offsetInEndSection": 664, 
            "text": " The patient with the V59M mutation successfully switched from insulin injections to oral glibenclamide; 2 years of follow-up revealed that the patient had intermediate developmental delay, epilepsy and neonatal diabetes (DEND) syndrome. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22145471", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 752, 
            "offsetInEndSection": 1078, 
            "text": "Approximately 20% have associated neurologic features: the most severe form, which includes epilepsy and developmental delay, is called developmental delay, epilepsy, and neonatal diabetes (DEND) syndrome and the milder form, with less severe developmental delay and without epilepsy, is designated intermediate DEND syndrome.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768671", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 434, 
            "offsetInEndSection": 646, 
            "text": "We have verified a lack of clinical response for both glycemic control and neurological features in an infant with permanent neonatal diabetes mellitus and DEND syndrome due to a V59A mutation in the KCNJ11 gene.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382304", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 663, 
            "offsetInEndSection": 939, 
            "text": "There is a striking genotype-phenotype relationship with specific Kir6.2 mutations being associated with transient neonatal diabetes, permanent neonatal diabetes alone, and a novel syndrome characterized by developmental delay, epilepsy, and neonatal diabetes (DEND) syndrome.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16123337", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 305, 
            "offsetInEndSection": 427, 
            "text": "In a few patients, KCNJ11 mutations cause a triad of developmental delay, epilepsy, and neonatal diabetes (DEND syndrome).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652641", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 160, 
            "text": "Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19169493", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 383, 
            "offsetInEndSection": 658, 
            "text": "It is proposed that some patients with KCNJ11 mutations have neurological features that are part of a discrete neurological syndrome termed developmental Delay, Epilepsy and Neonatal Diabetes (DEND), but there are also neurological consequences of chronic or acute diabetes. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16670688", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 234, 
            "text": "Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19686306", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 184, 
            "offsetInEndSection": 306, 
            "text": "In a few patients, KCNJ11 mutations cause a triad of developmental delay, epilepsy, and neonatal diabetes (DEND syndrome).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652641", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 223, 
            "offsetInEndSection": 435, 
            "text": "We have verified a lack of clinical response for both glycemic control and neurological features in an infant with permanent neonatal diabetes mellitus and DEND syndrome due to a V59A mutation in the KCNJ11 gene.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382304", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 383, 
            "offsetInEndSection": 657, 
            "text": "It is proposed that some patients with KCNJ11 mutations have neurological features that are part of a discrete neurological syndrome termed developmental Delay, Epilepsy and Neonatal Diabetes (DEND), but there are also neurological consequences of chronic or acute diabetes.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16670688", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1317, 
            "offsetInEndSection": 1466, 
            "text": "We report a case of developmental delay, epilepsy, and neonatal diabetes (DEND) syndrome that shows neurologic improvement with sulfonylurea therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17652641", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 512, 
            "offsetInEndSection": 692, 
            "text": "Some patients have DEND syndrome (developmental delay, epilepsy and neonatal diabetes) with the neurological features arising from mutated KATP channels in muscle, nerve and brain.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16019717", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 429, 
            "offsetInEndSection": 755, 
            "text": "Approximately 20% have associated neurologic features: the most severe form, which includes epilepsy and developmental delay, is called developmental delay, epilepsy, and neonatal diabetes (DEND) syndrome and the milder form, with less severe developmental delay and without epilepsy, is designated intermediate DEND syndrome.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768671", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 445, 
            "offsetInEndSection": 574, 
            "text": "Intermediate developmental delay, epilepsy and neonatal diabetes mellitus (DEND) syndrome as a result of a 59V>M Kir6.2 mutation.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20368737", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1290, 
            "offsetInEndSection": 1435, 
            "text": "Five patients with developmental delay, epilepsy and neonatal diabetes (DEND) syndrome had unique mutations not associated with other phenotypes.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16609879", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 430, 
            "offsetInEndSection": 756, 
            "text": "Approximately 20% have associated neurologic features: the most severe form, which includes epilepsy and developmental delay, is called developmental delay, epilepsy, and neonatal diabetes (DEND) syndrome and the milder form, with less severe developmental delay and without epilepsy, is designated intermediate DEND syndrome.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22768671", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 224, 
            "offsetInEndSection": 520, 
            "text": "We have verified a lack of clinical response for both glycemic control and neurological features in an infant with permanent neonatal diabetes mellitus and DEND syndrome due to a V59A mutation in the KCNJ11 gene. Thus, our case reinforces that most cases with DEND syndrome are insensitive to SU.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382304", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 513, 
            "offsetInEndSection": 693, 
            "text": "Some patients have DEND syndrome (developmental delay, epilepsy and neonatal diabetes) with the neurological features arising from mutated KATP channels in muscle, nerve and brain.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16019717", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 224, 
            "offsetInEndSection": 436, 
            "text": "We have verified a lack of clinical response for both glycemic control and neurological features in an infant with permanent neonatal diabetes mellitus and DEND syndrome due to a V59A mutation in the KCNJ11 gene.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23382304", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 384, 
            "offsetInEndSection": 658, 
            "text": "It is proposed that some patients with KCNJ11 mutations have neurological features that are part of a discrete neurological syndrome termed developmental Delay, Epilepsy and Neonatal Diabetes (DEND), but there are also neurological consequences of chronic or acute diabetes.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16670688", 
            "endSection": "abstract"
        }
    ]
}